Aelis Farma SA Cash Flow Conversion Efficiency
Aelis Farma SA cash flow conversion efficiency. Based on the latest financial reports, Aelis Farma SA (AELIS) has a cash flow conversion efficiency ratio of -0.635x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.88 Million ≈ $-4.54 Million USD) by net assets (€6.11 Million ≈ $7.15 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aelis Farma SA (2018–2024)
Cash flow conversion efficiency of Aelis Farma SA from 2018 to 2024. This chart illustrates how Aelis Farma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AELIS live share price for real-time trading data and today's change.
Aelis Farma SA Cash Flow Conversion Ratio Explained
Aelis Farma SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aelis Farma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aelis Farma SA ranked by their cash flow conversion efficiency. Also see AELIS company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Frigo-Pak Gida Maddeleri Sanayi ve Ticaret AS
IS:FRIGO
|
0.179x |
|
PATERSON RESOURCES LTD
F:U40
|
N/A |
|
WAPS Co. Ltd
KQ:196700
|
0.038x |
|
Luxbright AB
ST:LXB
|
-0.525x |
|
Media Investment Optimization SL
MC:MIO
|
-0.196x |
|
Advance Metals Ltd
AU:AVM
|
-0.047x |
|
Nanalysis Scientific Corp
V:NSCI
|
-0.010x |
|
Focus Lumber Bhd
KLSE:5197
|
0.025x |
Annual Cash Flow Conversion Efficiency for Aelis Farma SA (2018–2024)
The table below shows the annual cash flow conversion efficiency of Aelis Farma SA from 2018 to 2024. Review Aelis Farma SA (AELIS) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €10.12 Million ≈ $11.83 Million |
€-11.83 Million ≈ $-13.83 Million |
-1.170x | -22.67% |
| 2023-12-31 | €13.20 Million ≈ $15.43 Million |
€-12.59 Million ≈ $-14.71 Million |
-0.953x | -44.57% |
| 2022-12-31 | €19.79 Million ≈ $23.14 Million |
€-13.05 Million ≈ $-15.26 Million |
-0.659x | -103.12% |
| 2021-12-31 | €898.00K ≈ $1.05 Million |
€18.97 Million ≈ $22.18 Million |
21.125x | +505.27% |
| 2020-12-31 | €-710.00K ≈ $-830.06K |
€-2.48 Million ≈ $-2.90 Million |
3.490x | +245.50% |
| 2019-12-31 | €1.20 Million ≈ $1.41 Million |
€-2.89 Million ≈ $-3.38 Million |
-2.399x | -61.24% |
| 2018-12-31 | €2.38 Million ≈ $2.79 Million |
€-3.55 Million ≈ $-4.15 Million |
-1.488x | -- |
About Aelis Farma SA
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; an… Read more